William Towner
Internal Medicine · Los Angeles, CANPI 1538230412
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $743 of the $1,127 with a category attached, or 66.0%. 4 manufacturers reported payments, led by Merck at 59.1% of the total. Reporting peaked in 2020 at $666 and has fallen 60.1% since, to $266 in 2025.
Across 12 payments — averaging $93.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$666
- Viiv Healthcare Company$291
- Abbott$150
- Pfizer$20
Across 1,026 payments — averaging $26,669 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$12.1M
- Pfizer$6M
- Modernatx, Inc.$2.9M
- Janssen Research & Development, LLC$2.4M
- Viiv Healthcare Company$1.9M
- Merck$721K
- plus $1.3M from 4 others
What the payments were for
- Travel & lodging$36332%
- Food & beverage$74366%
- Gifts$202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 6 | $666 |
| Viiv Healthcare Company | 4 | $291 |
| Abbott | 1 | $150 |
| Pfizer | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,127 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Egrifta SvTesamorelin Acetate | 12 | $92,138 |
| JardianceEmpagliflozin | 21 | $9,340 |
| Spiriva RespimatTiotropium Bromide | 12 | $3,625 |
| Menveo A-C-Y-W-135-DipMening Vac A,c,y,w-135 Dip/Pf | 16 | $2,416 |
| Terazosin Hcl | 46 | $2,201 |
| Testosterone | 22 | $2,099 |
| Acyclovir | 56 | $1,644 |
| Atorvastatin Calcium | 126 | $1,480 |
| Ritonavir | 11 | $1,474 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,262 |
| Enoxaparin Sodium | 12 | $1,081 |
| Testosterone Cypionate | 12 | $901 |
| Azelastine Hcl | 25 | $637 |
| Gabapentin | 30 | $546 |
| Lisinopril | 34 | $443 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Los Angeles
- William HardyLos Angeles$704K
- Soha DolatabadiLos Angeles$458K
- Matthew HerrmannLos Angeles$384K
- Koppany VisnyeiLos Angeles$287K
- Jaime BetancourtLos Angeles$286K
- William KingLos Angeles$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.